



11. Drug monitoring and adverse events Friday, 31 October 2014, 12:45-14:15

Chairs: Siva Danaviah (South Africa), Ivan Solovic (Slovakia) Section: Tuberculosis

- OAP-280-31** **Therapeutic drug monitoring for first-line tuberculosis agents in adults**
12:45-12:55 K Wilby, M Ensom, F Marra (*Canada*)
- OAP-281-31** **Comparative characterisation of mycobacteria isolates using conventional and molecular methods**
12:55-13:05 P Nwadike, A.O. Koker, C C Onubogu, Phd, N. Nwokoye, N Onyejebu, M Gidado, O Idigbe (*Nigeria*)
- OAP-282-31** **A randomised controlled trial of protein calorie supplementation in HIV-infected patients with tuberculosis**
13:05-13:15 A Magohe, M Bakari, T Mackenzie, I Maro, A Urasa, K Hendricks, R Waddell, F C Von Reyn (*Tanzania, United Rep., USA*)
- OAP-283-31** **Genetic polymorphism NAT2 gene and incidence of hepatotoxic adverse reactions in patients with pulmonary tuberculosis**
13:15-13:25 A Kazakov (*Russian Federation*)
- OAP-284-31** **Paradoxical reactions in HIV-negative patients with spinal TB: our experience**
13:25-13:35 L Ramani, M Mehta, K Tiwari, M Darmalingam (*UK*)
- OAP-285-31** **No evidence of QT prolongation with a four-month TB regimen with gatifloxacin at 400mg/day substituting for ethambutol**
13:35-13:45 P Olliaro, C Merle, B Bah, F Kassa, T Mthiyane, A Ndiaye, E Amukoye, K Fielding (*Switzerland, UK, Guinea, Benin, Senegal*)
- OAP-286-31** **Pharmacokinetic and safety/tolerability study of higher oral and intravenous doses of rifampicin in adult tuberculous meningitis patients**
13:45-13:55 vyck Yunivita, S Dian, A.R Ganiem, E Hayati, T.H Achmad, R Van Crevel, R Aarnoutse, R Ruslami (*Indonesia, Netherlands*)
- OAP-287-31** **Rapid oral desensitisation: alternative therapeutic very useful in major anti-tuberculosis drugs allergy**
13:55-14:05 H Daghfous, Z Haifa, S Ben Saad, moun Ben Khelifa, F Tritar (*Tunisia*)
- 14:05-14:15 Discussion